Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.
On 23 December 2005, orphan designation (EU/3/05/338) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for dasatinib for the treatment of acute lymphoblastic leukaemia.
Dasatinib has been authorised in the EU as Sprycel since 20 November 2006.
Key facts
Active substance |
dasatinib
|
Medicine name |
Sprycel
|
Intended use |
Treatment of acute lymphoblastic leukaemia
|
Orphan designation status |
Expired
|
EU designation number |
EU/3/05/338
|
Date of designation |
23/12/2005
|
Sponsor |
Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom Tel. +44 (0)1895 523740 Fax +44 (0)1895 523677 E-mail: medical.information@bms.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: